| 产品描述: | Saruparib (AZD5305) is a potent, orally active and selective PARP inhibitor and trapper with IC50 values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair |
| 靶点: |
PARP1:3 nM (IC50);PARP2:1400 nM (IC50);PARP |
| 体外研究: |
Saruparib (AZD5305) (0.1 nM-100 μM) 通过选择性阻断 PARP1 酶活性来抑制 A549 WT 细胞的PARylation,IC50 值为 2.3 nM。 AZD5305 (0.1 nM-100 μM) 是 PARP1 的有效选择性捕集剂,以个位数纳摩尔浓度剂量依赖性捕集 PARP1。 AZD5305 (0.1 nM-100 μM; 48 h; DLD1 WT and DLD1 BRCA2-/-) 针对 HRR 缺陷的癌细胞具有抗增殖活性,诱导 DNA 损伤积累和细胞周期阻滞 |
| 体内研究: |
Saruparib (AZD5305) (0.01-0.3 mg/kg; p.o.; 每天,持续35 天; 雌性 Han Wistar 大鼠) 在体内 BRCAm 异种移植物和 PDX 模型中显示持续的抗肿瘤活性。 Animal Model: Female Han Wistar rats with BRCAm xenograft and PDX models (12-13 weeks of age) Dosage: 0.01, 0.03, 0.1, and 0.3 mg/kg Administration: Oral administration; daily, for 35 days Result: Had antitumor efficacy in a dose-dependent manner. |
| 参考文献: |
1. Illuzzi G, et, al. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. 2. Johannes JW, et, al. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. J Med Chem. 2021 Oct 14;64(19):14498-14512. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.46 ml |
12.3 ml |
24.601 ml |
| 5 mM |
0.492 ml |
2.46 ml |
4.92 ml |
| 10 mM |
0.246 ml |
1.23 ml |
2.46 ml |
| 50 mM |
0.049 ml |
0.246 ml |
0.492 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |